Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCIPIT
2024-518447-38-00Phase 2Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Start
- Oct 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in cerebral palsy (CP) and Muscle spasm, sponsored by Azienda Ospedaliera Universitaria Integrata Verona. Primary endpoint: Change in Ashworth scale per injection cycle. Planned start Oct 2024; status: authorised.
02
Drugs
botulinum toxin type A
03
Conditions
cerebral palsy (CP)Muscle spasm
Beyond the preview
Go deeper on 2024-518447-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518447-38-00.